Patients with higher risk disease, which was categorized as patients with a stage 4 tumor at an age over 1 year or stage 1, 2, 3, or 4S tumors with MYCN amplification, also had lower N-cadherin mRNA expression compared to low-risk patients (p = 0.048). This evidence concerns the gene CDH2 and neoplasm.